GeNeuro Initiates Phase 2a Study with GNbAC1 in Type 1 Diabetes in Australia
Geneva (Switzerland), April 18, 2017 : GeNeuro (Euronext Paris : CH0308403085 – GNRO), a biopharmaceutical company developing new treatments for neurological disorders and autoimmune diseases, announced today the initiat ...